Latest news with #IRAD
Zawya
03-07-2025
- Politics
- Zawya
Cameroon's hidden green treasures unveiled in a book
In a powerful moment for conservation, the book 'Important Plant Areas of Cameroon' was officially launched on 18 June during UK - Cameroon Climate Week. This groundbreaking publication reveals a stunning yet sobering reality: over 850 endangered plant species are spread across 49 critical biodiversity hotspots in Cameroon. Co-authored by experts from Cameroon's Institute of Agricultural Research for Development (IRAD) National Herbarium, and the Royal Botanic Gardens, Kew, the book positions Cameroon as Africa's most tropically diverse nation. From lush rainforests to arid deserts, the country's ecosystems are as varied as they are vital. Yet, this rich biodiversity faces mounting threats. 10% of Cameroon's plant species are now endangered, and the country holds the highest number of threatened trees on the continent. The culprits? Expanding mining operations, aggressive logging, and the relentless spread of palm oil plantations are rapidly eroding Cameroon's forests. These activities not only endanger plant life but also jeopardize the ecological balance of the entire Congo Basin. British High Commissioner Matt Woods used the book's launch to spotlight Cameroon's critical role in global climate discussions. He urged the international community to amplify Cameroon's voice at major forums like COP30 and called for stronger global support to safeguard the Congo Basin's irreplaceable biodiversity. Speaking during the book launch, the representative of Royal Botanical Gardens in Kew, Prof. Philip Stevenson said: "It's been a fantastic week of new collaboration. We've been working with IRAD National Herbarium and developing opportunities to extend our reach and do more work here in Cameroon." This book is more than a catalogue of rare plants; it is a call to action. As the world grapples with climate change and biodiversity loss, Cameroon's green treasures remind us of what's at stake and what we still have the power to protect. Distributed by APO Group on behalf of British High Commission - Yaounde.
Time of India
05-05-2025
- Politics
- Time of India
SC directs road transport ministry to publish ‘Road Accidents in India of 2023' by August
Supreme Court NEW DELHI: Supreme Court has directed the road transport and highways ministry to publish the annual report of 'Road Accidents in India of 2023' by Aug and said such reports should be made public within six month after the end of every calendar year so that these can be 'useful'. Interestingly, the National Crime Records Bureau, which comes under the home ministry, has also not yet published the Accidental Deaths and Suicides in India report of 2023, even one and a half years after the end of that calendar year. The SC direction to the road transport ministry for publishing the report came after the govt informed a bench of Justices Abhay S Oka and Ujjal Bhuyan that the 'process of publication of the report is going on'. While granting time till Aug, the court said, 'We also direct MoRTH to ensure that such annual reports are published within a period of six months from expiry of the calendar year. Only if such reports are published with promptness, the same can be useful.' Road safety experts and activists have raised questions on the delay in publication of the report which is crucial for deciding on interventions. They have also urged the govt to make some data collected through the 'Integrated Road Accident Database (IRAD)', which details cause of crashes with exact location, public so that different entities can take corrective steps. 'These data should be made public rather than giving them to a couple of entities for their advantage, if the target is to make road safety a mass movement,' said one of them. Earlier this year, the home ministry had informed Rajya Sabha that 'data validation for the 2023 report (NCRB) is in the final stage'.
Yahoo
28-01-2025
- Business
- Yahoo
IRADIMED's (NASDAQ:IRMD) investors will be pleased with their solid 156% return over the last five years
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose your money. But on a lighter note, a good company can see its share price rise well over 100%. For example, the IRADIMED CORPORATION (NASDAQ:IRMD) share price has soared 138% in the last half decade. Most would be very happy with that. Also pleasing for shareholders was the 14% gain in the last three months. Now it's worth having a look at the company's fundamentals too, because that will help us determine if the long term shareholder return has matched the performance of the underlying business. View our latest analysis for IRADIMED There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. Over half a decade, IRADIMED managed to grow its earnings per share at 15% a year. This EPS growth is slower than the share price growth of 19% per year, over the same period. This suggests that market participants hold the company in higher regard, these days. And that's hardly shocking given the track record of growth. The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image). It's probably worth noting that the CEO is paid less than the median at similar sized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. Dive deeper into the earnings by checking this interactive graph of IRADIMED's earnings, revenue and cash flow. It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. As it happens, IRADIMED's TSR for the last 5 years was 156%, which exceeds the share price return mentioned earlier. And there's no prize for guessing that the dividend payments largely explain the divergence! It's good to see that IRADIMED has rewarded shareholders with a total shareholder return of 40% in the last twelve months. And that does include the dividend. That gain is better than the annual TSR over five years, which is 21%. Therefore it seems like sentiment around the company has been positive lately. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider risks, for instance. Every company has them, and we've spotted 2 warning signs for IRADIMED you should know about. But note: IRADIMED may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
